secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImageneBio, Inc. (IMA)
CIK:        0001835579
Form:       8-K
Filed at:   2025-07-25T23:59:59+00:00
Accession:  0001193125-25-165170
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Ikena Oncology completes merger with Inmagene, becomes ImageneBio, raises $75M private placement
--------------------------------------------------------------------------------

- Merger closed July 25, 2025; combined company renamed ImageneBio, Inc., trading on Nasdaq under IMA starting July 28.
- Concurrent $75.0M private placement from investors including Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors.
- Legacy Inmagene holders own ~55% (pre-financing) or ~43.1% (post-financing); Ikena holders own ~45% (pre) or ~35.3% (post); new investors own ~21.6%.
- ImageneBio to advance IMG-007 Phase 2b trial in moderate-to-severe atopic dermatitis; topline readout expected Q4 2026.
- Kristin Yarema, Ph.D. appointed CEO; Ikena implemented a 1-for-12 reverse stock split prior to closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835579/000119312525165170/0001193125-25-165170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835579/000119312525165170/d62567d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-165170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer